Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference
Beam Therapeutics presented topline clinical data for BEAM-302 at the American Thoracic Society 2026 International Conference, highlighting durable restoration of normal AAT function in patients with Alpha-1 Antitrypsin Deficiency. The data, covering 29 patients treated in the Phase 1/2 trial, demonstrated that a single dose can correct the PiZ mutation at the DNA level, addressing both lung and liver manifestations of the disease.
Key figures
- Drug Name
- BEAM-302
- Phase Of Trial
- Phase 1/2
- Patients treated
- 29
- Pivotal start window
- H2 2026
- Planned pivotal enrollment
- 50
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.